Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Pr. da Cruz Vermelha, 23 - Centro, Rio de Janeiro - RJ, 20230-130
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Adriana Melo
Flora de Moraes Lino da Silva
Open studies
Lung cancer
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) - INTerpath-009 - Merck Sharp & Dohme LLCSee more
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% - RELATIVITY1093 - Bristol-Myers SquibbSee more
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) - KANDLELIT-004 - Merck Sharp & Dohme LLCSee more
Breast Cancer
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds - MorphineGEL - Instituto Nacional de Cancer, BrazilSee more
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) - MK-2870-032 - Merck Sharp & Dohme LLCSee more
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer - INAVO123 - Hoffmann-La RocheSee more
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Cervical cancer
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer - Nivolumab - Hospital Israelita Albert EinsteinSee more
Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer - AddChemo - Hospital do CoracaoSee more
Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. - ACCESS-I - Instituto Nacional de Cancer, BrazilSee more
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) - TroFuse-036 - Merck Sharp & Dohme LLCSee more
Leukemia
PTCy and ATG for MSD and MUD Transplants - PTCy-ATG-001 - Instituto Nacional de Cancer, BrazilSee more
PTCy and ATG for MSD and MUD Transplants - PTCy-ATG-001 - Instituto Nacional de Cancer, BrazilSee more
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - BELLWAVE-003 - Merck Sharp & Dohme Corp.See more
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) - TroFuse-033 - Merck Sharp & Dohme LLCSee more
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Ovarian cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) - TroFuse-022 - Merck Sharp & Dohme LLCSee more
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
PTCy and ATG for MSD and MUD Transplants - PTCy-ATG-001 - Instituto Nacional de Cancer, BrazilSee more
Myelodysplastic Syndromes
PTCy and ATG for MSD and MUD Transplants - PTCy-ATG-001 - Instituto Nacional de Cancer, BrazilSee more
Graft versus Host Disease
PTCy and ATG for MSD and MUD Transplants - PTCy-ATG-001 - Instituto Nacional de Cancer, BrazilSee more
Rare diseases
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - BELLWAVE-003 - Merck Sharp & Dohme Corp.See more
Hpv
Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer - AddChemo - Hospital do CoracaoSee more
Colorectal cancer
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait - CCHOWW - Hospital Alemão Oswaldo CruzSee more
Solid tumors
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
